Cryoport, Inc. (CYRX) intrinsic value & 10-year financials

Cryoport, Inc. (CYRX) has a Graham intrinsic value of $46.50 per share. At $16.84 on Oct 17, 2026, the stock trades 64% below that value. Over the last 10 fiscal years revenue grew 45.9% a year to $176.2M, with an average return on invested capital of -630.1%.

Graham intrinsic value
$46.50
Share price (Oct 17, 2026)
$16.84
Price vs Graham value
64% below
Market cap
$843.2M
Revenue (FY2025)
$176.2M
Revenue growth (10-yr CAGR)
45.9%
ROIC (10-yr avg)
-630.1%
Free cash flow (FY2025)
-$25.0M

CYRX 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $176.2M $78.3M $1.40 -$25.0M -20.9% -10.4%
FY2024 $228.4M -$114.8M -$2.49 -$33.6M -57.3% -30.0%
FY2023 $233.3M -$99.6M -$2.21 -$39.5M -49.4% -22.6%
FY2022 $237.3M -$37.3M -$0.93 -$24.0M -13.4% -6.0%
FY2021 $222.6M -$275.5M -$6.19 -$15.8M -8.0% -4.0%
FY2020 $78.7M -$32.7M -$1.94 -$23.8M -38.1% -13.4%
FY2019 $33.9M -$18.3M -$0.55 -$6.7M -52.1% -41.9%
FY2018 $19.6M -$9.6M — -$6.3M -44.0% -690.1%
FY2017 $12.0M -$7.9M — -$5.3M -66.0% -2601.3%
FY2016 $5.9M -$9.8M — -$7.4M -148.6% -2881.0%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Cryoport, Inc. is a consistent compounder, expanding top-line revenue at 45.9% annually over the past decade.

Cryoport, Inc. has historically struggled to out-earn its cost of capital, averaging just -19.0% ROIC.

Cryoport, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Cryoport, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $46.50 per share.

CYRX stock: frequently asked questions

What is the intrinsic value of Cryoport, Inc. (CYRX) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, CYRX's intrinsic value is about $46.50 per share.

Is CYRX stock undervalued?

At $16.84 (close on Oct 17, 2026), CYRX trades 64% below its Graham value of $46.50. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Cryoport, Inc. grown?

Revenue went from $5.9M in fiscal 2016 to $176.2M in fiscal 2025, a compound annual growth rate of 45.9%. Net income was $78.3M in fiscal 2025.

Does Cryoport, Inc. generate free cash flow?

Cryoport, Inc. generated -$25.0M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 10 reported years.

What is CYRX's return on invested capital?

Average ROIC over the last 10 fiscal years was -630.1%, and average return on equity was -54.9%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this CYRX data come from?

From Cryoport, Inc.'s annual 10-K filings on SEC EDGAR, most recently filed Aug 6, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks